Complicated Urinary Tract Infection Treatment Global Market Report 2025

The complicated urinary tract infection treatment market size has grown strongly in recent years. It will grow from $8.87 billion in 2024 to $9.47 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. The growth during the historical period can be attributed to factors such as the increasing prevalence of urinary tract infections, a rise in cases of antibiotic resistance, a growing geriatric population, higher hospitalization rates, and greater awareness about UTIs.

The complicated urinary tract infection treatment market size is expected to see strong growth in the next few years. It will grow to $12.13 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. The growth during the forecast period can be attributed to factors such as the growing prevalence of multidrug-resistant pathogens, an increasing focus on precision medicine, rising healthcare expenditure, greater use of rapid diagnostic testing, government initiatives, and funding for research. Key trends during this period include advancements in diagnostic techniques, expanding healthcare access in emerging markets, the development of novel antibiotics, technological innovations in diagnostic tools, and the adoption of combination therapies.

The increasing prevalence of chronic kidney disease (CKD) is expected to drive growth in the complicated urinary tract infection treatment market. CKD is a long-term condition marked by the gradual decline in kidney function over time. The rise in CKD cases is largely due to the growing rates of diabetes, hypertension, aging populations, and lifestyle factors such as obesity and smoking. Treatment for complicated urinary tract infections is crucial for CKD patients as it helps prevent severe infections such as pyelonephritis, which can worsen kidney damage, impair renal function, and accelerate the progression of CKD. This treatment reduces the risk of further complications and hospitalizations. For example, in December 2024, the Australian Institute of Health and Welfare reported that CKD was responsible for approximately 21,800 deaths in Australia in 2022. Moreover, in May 2024, Kidney Care UK stated that chronic kidney disease causes 40,000 to 45,000 premature deaths each year in the UK. Thus, the rising incidence of CKD is driving the growth of the complicated urinary tract infection treatment market.

Key companies in the complicated urinary tract infection treatment market are focusing on addressing antibiotic resistance through the development of novel antibiotics to improve treatment effectiveness and tackle emerging multidrug-resistant pathogens. Anti-infective therapies for complicated urinary tract infections involve using targeted antibiotics or antimicrobial agents to control infections, particularly in severe cases where the kidneys are affected. For instance, in February 2024, Allecra Therapeutics, a Germany-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved EXBLIFEP (cefepime/enmetazobactam) for treating complicated urinary tract infections in adults. The company also secured a five-year marketing exclusivity extension under the GAIN Act, which encourages the development of new anti-infective therapies. Clinical studies showed that 79.1% of patients treated with cefepime/enmetazobactam achieved a composite response (clinical cure and microbiological eradication), compared to 58.9% in those treated with piperacillin/tazobactam.

In June 2024, Orchid Pharma Limited, an India-based pharmaceutical company, partnered with Cipla Limited to launch cefepime/enmetazobactam in India. This collaboration aims to leverage Cipla’s distribution network to enhance the availability of cefepime/enmetazobactam, an antibiotic used to treat complicated urinary tract infections, including pyelonephritis. Cipla, a prominent India-based pharmaceutical company, focuses on providing advanced antibiotics and innovative healthcare solutions for treating complicated urinary tract infections.

Major players in the complicated urinary tract infection treatment market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., AstraZeneca PLC, Fresenius Kabi AG, GlaxoSmithKline plc, bioMérieux SA, Shionogi & Co. Ltd., Cipla Limited, Santen Pharmaceutical Co. Ltd., Orchid Pharma Limited, Melinta Therapeutics Inc., Spero Therapeutics Inc., Nabriva Therapeutics AG, Venatorx Pharmaceuticals Inc., Recce Pharmaceuticals Ltd, MerLion Pharmaceuticals Pte. Ltd., Entasis Therapeutics Holdings Inc., Allecra Therapeutics GmbH, Allergan Inc.

North America was the largest region in the complicated urinary tract infection treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in complicated urinary tract infection report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the complicated urinary tract infection market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Complicated urinary tract infection (UTI) treatment refers to the management of urinary tract infections in individuals with underlying conditions that increase the risk of treatment failure. This treatment involves using targeted antibiotics and supportive therapies to address infections caused by resistant pathogens or other complications. It is particularly used for severe UTIs in patients with structural abnormalities, immunocompromised conditions, or catheter use, ensuring effective infection control and preventing further complications.

The main drug types for complicated urinary tract infection treatment include penicillin and combinations, quinolones, cephalosporins, azoles and amphotericin B, and nitrofurans. Penicillin and combinations consist of antibiotics derived from penicillin, often combined with beta-lactamase inhibitors to enhance their effectiveness against resistant bacteria. These treatments are distributed through various channels, such as hospital pharmacies, gynecology and urology clinics, and drug stores. They are used for a range of conditions, including urethritis, cystitis, and pyelonephritis.

The complicated urinary tract infection treatment market research report is one of a series of new reports that provides complicated urinary tract infection treatment market statistics, including the complicated urinary tract infection treatment industry global market size, regional shares, competitors with the complicated urinary tract infection treatment market share, detailed complicated urinary tract infection treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the complicated urinary tract infection treatment industry. This complicated urinary tract infection treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The complicated urinary tract infection treatment market consists of sales of antibiotics, antifungals, and combination therapy. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.